Xenetic Biosciences Inc (XBIO) 4.4500 $XBIO
Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors
BusinessWire - Mon Jul 11, 7:00AM CDT
Xenetic Biosciences, Inc. (OTCQB:XBIO) ("Xenetic" or the "Company"
, a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has appointed Jeffrey F. Eisenberg to the Company's Board of Directors.
Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market
BusinessWire - Wed Jun 01, 6:30AM CDT
Xenetic Biosciences, Inc. (OTCQB: XBIO) ("Xenetic" or "the Company" , a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its Board of Directors has approved a proportional 1-for-33 reduction and reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market ("NASDAQ" . The Company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on Wednesday June 1, 2016, contingent upon final approval from the Financial Industry Regulatory Authority (FINRA).
PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis
Marketwired - Fri Apr 01, 7:14AM CDT
PJSC Pharmsynthez (MCX: LIFE), a St. Petersburg, Russia based pharmaceutical company developing next generation vaccines and biologics has completed follow up and data analysis from a first-in-human, proof-of-concept and dose-escalation study of CD206-targeted proprietary liposomal oligopeptides in multiple sclerosis (MS) patients who are resistant to first-line disease modifying therapies. Xemys(TM) uses Xenetic Biosciences (OTCQB: XBIO) patented ImuXen(TM) technology.
LIFE: 3.41 (+0.44), OPK: 9.95 (+0.06)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 11.45 (+0.12), VRTX: 97.00 (+0.79), PFE: 36.89 (+0.22), GSK: 45.07 (-0.11), CNCE: 11.49 (-0.28), GLPG: 55.17 (-0.12), CYCC: 5.03 (+0.16), PTI: 11.10 (+0.34), SHPG: 194.12 (+2.69), PULM: 2.12 (-0.05), MRK: 58.66 (+0.23), NVLS: 4.68 (-0.10), PTCT: 5.97 (+0.20), KMDA: 3.96 (unch), AKTX: 9.30 (+0.45), NVS: 83.26 (+1.18)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 13.13 (+0.43), GSK: 45.07 (-0.11), SYN: 1.75 (-0.03), OPXA: 4.16 (-0.02), FWP: 20.07 (+0.46), TEVA: 53.50 (-1.29), ABBV: 66.23 (+1.51), NVS: 83.26 (+1.18)
Baxalta to Initiate a First-in-Human Clinical Trial of BAX 826, an Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing for Hemophilia A
BusinessWire - Fri Nov 20, 11:47AM CST
--Baxalta's second investigational extended half-life candidate based on ADVATE [Antihemophilic Factor (Recombinant)] uses proprietary polysialic acid (PSA) technology that aims to extend dosing intervals
BXLT: 46.02 (-0.18)
Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa(TM)
Thomson Reuters ONE - Mon Nov 16, 11:41AM CST
LEXINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the "Company" , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that it has entered into an Asset Purchase Agreement (the "APA" with AS Kevelt, an Estonian biotech company ("Kevelt" and OJSC Pharmsynthez ("Pharmsynthez", and together with Kevelt, "Sellers" . Pursuant to the APA, the Sellers will transfer to the Company certain intellectual property rights with respect to Virexxa(TM), and the Company will receive the worldwide rights to develop, market and license Virexxa for all uses, except for certain excluded uses within the Commonwealth of Independent States (the "CIS" , in exchange for 111.5 million shares of Company common stock and certain other consideration. Virexxa is a Phase II oncology drug candidate which is under investigation for the treatment of certain endometrial cancers. As part of this total consideration, the Company will also acquire Kevelt's U.S. Orphan Drug designation for the use of Virexxa in the treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
Thomson Reuters ONE - Wed Oct 07, 6:20AM CDT
LEXINGTON, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the "Company" , a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that several of its major shareholders including Baxalta Incorporated (NYSE:BXLT) (formerly Baxter Healthcare), SynBio LLC and Serum Institute of India Limited have entered into Lock-up Letter Agreements (the "Lock-up" . Under the Lock-up each of the shareholders has agreed to not sell any of its shares currently held before June 30, 2016 and then further to limit the sale of its shares in the Company for an additional six months (to December 2016) to a price of no less than $1.25 per share. The Lock-up covers more than 58% of the issued shares of the Company's common stock.
BXLT: 46.02 (-0.18)
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia
Thomson Reuters ONE - Wed Sep 16, 6:00AM CDT
Trial expands into South Africa
Non-Hodgkin Lymphoma - Pipeline Review, H1 2015
M2 - Thu Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njqxnc/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 110 companies mentioned in this comprehensive report: - AB Science - AbbVie - BioAtla, - Biogenomics - Calimmune - Calithera Biosciences - Dicerna Pharmaceuticals - Eisai Co. - Eli Lilly and Company - F. Hoffmann-La Roche - Formula Pharmaceuticals - Galderma - Gamida Cell - Hetero Drugs - Hospira - iDD biotech - Immune Design - Johnson & Johnson - Juno Therapeutics - Kainos Medicine - Karyopharm Therapeutics - MedImmune - Merck & Co. - Nordic Nanovector - Novartis - OncoSec Medical - Onxeo - Pfizer - Pharma Mar - Richter Gedeon - Sanofi - Tekmira Pharmaceuticals - Vivia Biotech - Xenetic Biosciences - Zymeworks For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/njqxnc/nonhodgkin
IMDZ: 7.67 (-0.23), DRNA: 3.21 (-0.09), TKMR: 10.83 (+0.58), LLY: 82.89 (-0.04), JNJ: 125.23 (+0.77), MRK: 58.66 (+0.23), CALA: 3.17 (-0.03), ONCS: 1.82 (+0.03), JUNO: 30.93 (+1.02), KPTI: 7.38 (+0.02), NVS: 83.26 (+1.18)
Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out
Thomson Reuters ONE - Wed Sep 09, 6:00AM CDT
LEXINGTON, Mass., Sept. 09, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its contracts and arrangements with Baxter Healthcare SA ("Baxter SA" and Baxter Healthcare Corporation (together referred to as "Baxter" (NYSE:BAX) have now been assigned to Baxalta Incorporated (NYSE:BXLT) ("Baxalta" as part of the spin out of the company's biopharmaceutical business.
BAX: 48.02 (-0.20), BXLT: 46.02 (-0.18)
Xenetic Biosciences, Inc. - "Why Global Healthcare Companies Have Invested in Xenetic Biosciences"
ACCESSWIRE - Thu Aug 06, 8:04AM CDT
NEW YORK, NY / ACCESSWIRE / August 6, 2015 / Xenetic Biosciences, Inc. (OTCQB: XBIO) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Scott Maguire, MBA. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BAX: 48.02 (-0.20)
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia
Thomson Reuters ONE - Tue Jul 14, 5:00AM CDT
Hemoglobin Levels Rose and were Maintained in Therapeutic Range
Xenetic Biosciences Completes $3,000,000 Bridge Note Financing
Thomson Reuters ONE - Wed Jul 08, 11:53AM CDT
LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. ("Xenetic" or the "Company" (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has completed a $3,000,000 bridge note financing. The financing was concluded with OJSC Pharmsynthez ("Pharmsynthez" , a collaborative partner of Xenetic and an affiliate of Xenetic's largest shareholder SynBio LLC ("Synbio" and was arranged directly between the managements of Xenetic and Pharmsynthez on a commission free basis.
Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors
BusinessWire - Mon Jul 11, 7:00AM CDT
Xenetic Biosciences, Inc. (OTCQB:XBIO) ("Xenetic" or the "Company"
, a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has appointed Jeffrey F. Eisenberg to the Company's Board of Directors. Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market
BusinessWire - Wed Jun 01, 6:30AM CDT
Xenetic Biosciences, Inc. (OTCQB: XBIO) ("Xenetic" or "the Company"
, a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that its Board of Directors has approved a proportional 1-for-33 reduction and reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market ("NASDAQ" . The Company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on Wednesday June 1, 2016, contingent upon final approval from the Financial Industry Regulatory Authority (FINRA). PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis
Marketwired - Fri Apr 01, 7:14AM CDT
PJSC Pharmsynthez (MCX: LIFE), a St. Petersburg, Russia based pharmaceutical company developing next generation vaccines and biologics has completed follow up and data analysis from a first-in-human, proof-of-concept and dose-escalation study of CD206-targeted proprietary liposomal oligopeptides in multiple sclerosis (MS) patients who are resistant to first-line disease modifying therapies. Xemys(TM) uses Xenetic Biosciences (OTCQB: XBIO) patented ImuXen(TM) technology.
LIFE: 3.41 (+0.44), OPK: 9.95 (+0.06)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 11.45 (+0.12), VRTX: 97.00 (+0.79), PFE: 36.89 (+0.22), GSK: 45.07 (-0.11), CNCE: 11.49 (-0.28), GLPG: 55.17 (-0.12), CYCC: 5.03 (+0.16), PTI: 11.10 (+0.34), SHPG: 194.12 (+2.69), PULM: 2.12 (-0.05), MRK: 58.66 (+0.23), NVLS: 4.68 (-0.10), PTCT: 5.97 (+0.20), KMDA: 3.96 (unch), AKTX: 9.30 (+0.45), NVS: 83.26 (+1.18)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/chd4px/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsing Remitting Multiple Sclerosis (RRMS) Overview - Therapeutics Development - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview - Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies - Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes - Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biocon Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline Plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Xenetic Biosciences plc - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/chd4px/relapsing
MAPI: (), RDHL: 13.13 (+0.43), GSK: 45.07 (-0.11), SYN: 1.75 (-0.03), OPXA: 4.16 (-0.02), FWP: 20.07 (+0.46), TEVA: 53.50 (-1.29), ABBV: 66.23 (+1.51), NVS: 83.26 (+1.18)
Baxalta to Initiate a First-in-Human Clinical Trial of BAX 826, an Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing for Hemophilia A
BusinessWire - Fri Nov 20, 11:47AM CST
--Baxalta's second investigational extended half-life candidate based on ADVATE [Antihemophilic Factor (Recombinant)] uses proprietary polysialic acid (PSA) technology that aims to extend dosing intervals
BXLT: 46.02 (-0.18)
Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa(TM)
Thomson Reuters ONE - Mon Nov 16, 11:41AM CST
LEXINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the "Company"
, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that it has entered into an Asset Purchase Agreement (the "APA" with AS Kevelt, an Estonian biotech company ("Kevelt" and OJSC Pharmsynthez ("Pharmsynthez", and together with Kevelt, "Sellers" . Pursuant to the APA, the Sellers will transfer to the Company certain intellectual property rights with respect to Virexxa(TM), and the Company will receive the worldwide rights to develop, market and license Virexxa for all uses, except for certain excluded uses within the Commonwealth of Independent States (the "CIS" , in exchange for 111.5 million shares of Company common stock and certain other consideration. Virexxa is a Phase II oncology drug candidate which is under investigation for the treatment of certain endometrial cancers. As part of this total consideration, the Company will also acquire Kevelt's U.S. Orphan Drug designation for the use of Virexxa in the treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy. Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
Thomson Reuters ONE - Wed Oct 07, 6:20AM CDT
LEXINGTON, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the "Company"
, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that several of its major shareholders including Baxalta Incorporated (NYSE:BXLT) (formerly Baxter Healthcare), SynBio LLC and Serum Institute of India Limited have entered into Lock-up Letter Agreements (the "Lock-up" . Under the Lock-up each of the shareholders has agreed to not sell any of its shares currently held before June 30, 2016 and then further to limit the sale of its shares in the Company for an additional six months (to December 2016) to a price of no less than $1.25 per share. The Lock-up covers more than 58% of the issued shares of the Company's common stock. BXLT: 46.02 (-0.18)
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia
Thomson Reuters ONE - Wed Sep 16, 6:00AM CDT
Trial expands into South Africa
Non-Hodgkin Lymphoma - Pipeline Review, H1 2015
M2 - Thu Sep 10, 10:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njqxnc/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 110 companies mentioned in this comprehensive report: - AB Science - AbbVie - BioAtla, - Biogenomics - Calimmune - Calithera Biosciences - Dicerna Pharmaceuticals - Eisai Co. - Eli Lilly and Company - F. Hoffmann-La Roche - Formula Pharmaceuticals - Galderma - Gamida Cell - Hetero Drugs - Hospira - iDD biotech - Immune Design - Johnson & Johnson - Juno Therapeutics - Kainos Medicine - Karyopharm Therapeutics - MedImmune - Merck & Co. - Nordic Nanovector - Novartis - OncoSec Medical - Onxeo - Pfizer - Pharma Mar - Richter Gedeon - Sanofi - Tekmira Pharmaceuticals - Vivia Biotech - Xenetic Biosciences - Zymeworks For more information, including full list of companies mentioned, please visit http://www.researchandmarkets.com/research/njqxnc/nonhodgkin
IMDZ: 7.67 (-0.23), DRNA: 3.21 (-0.09), TKMR: 10.83 (+0.58), LLY: 82.89 (-0.04), JNJ: 125.23 (+0.77), MRK: 58.66 (+0.23), CALA: 3.17 (-0.03), ONCS: 1.82 (+0.03), JUNO: 30.93 (+1.02), KPTI: 7.38 (+0.02), NVS: 83.26 (+1.18)
Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out
Thomson Reuters ONE - Wed Sep 09, 6:00AM CDT
LEXINGTON, Mass., Sept. 09, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces that its contracts and arrangements with Baxter Healthcare SA ("Baxter SA"
and Baxter Healthcare Corporation (together referred to as "Baxter" (NYSE:BAX) have now been assigned to Baxalta Incorporated (NYSE:BXLT) ("Baxalta" as part of the spin out of the company's biopharmaceutical business. BAX: 48.02 (-0.20), BXLT: 46.02 (-0.18)
Xenetic Biosciences, Inc. - "Why Global Healthcare Companies Have Invested in Xenetic Biosciences"
ACCESSWIRE - Thu Aug 06, 8:04AM CDT
NEW YORK, NY / ACCESSWIRE / August 6, 2015 / Xenetic Biosciences, Inc. (OTCQB: XBIO) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Scott Maguire, MBA. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BAX: 48.02 (-0.20)
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia
Thomson Reuters ONE - Tue Jul 14, 5:00AM CDT
Hemoglobin Levels Rose and were Maintained in Therapeutic Range
Xenetic Biosciences Completes $3,000,000 Bridge Note Financing
Thomson Reuters ONE - Wed Jul 08, 11:53AM CDT
LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. ("Xenetic" or the "Company"
(OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has completed a $3,000,000 bridge note financing. The financing was concluded with OJSC Pharmsynthez ("Pharmsynthez" , a collaborative partner of Xenetic and an affiliate of Xenetic's largest shareholder SynBio LLC ("Synbio" and was arranged directly between the managements of Xenetic and Pharmsynthez on a commission free basis. 
